FWL Investment Management’s Recursion Pharmaceuticals RXRX Stock Holding History

FWL Investment Management’s Portfolio RXRX Stock Details RXRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$202	Hold	55	–	–	﹤0.01%	498
2026 Q1	$169	Hold	55	–	–	﹤0.01%	342
2025 Q4	$225	Sell	55 -745	-93%	-$3.69K	﹤0.01%	361
2025 Q3	$3.9K	Buy	800 +30	+4%	+$158	﹤0.01%	296
2025 Q2	$3.9K	Hold	770	–	–	﹤0.01%	271
2025 Q1	$4.07K	Buy	770 +145	+23%	+$1.06K	﹤0.01%	257
2024 Q4	$4.22K	Buy	+625	New	+$4.2K	﹤0.01%	274

Other funds holding RXRX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

SoftBank Group Tokyo, Japan $18.2B AUM 177.65% 1-Year Est. Return

MCMU

MIC Capital Management (UK) London, United Kingdom $394M AUM 25.64% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

FWL Investment Management's RXRX Position: Q2 2026 in Review

FWL Investment Management held its Recursion Pharmaceuticals (RXRX) position steady in Q2 2026 at 55 shares worth $202. The position accounts for ﹤0.01% of the portfolio, ranked #498.

FWL Investment Management first reported a position in RXRX in Q4 2024 and has held it in 7 quarters since. The position peaked at $4.22K in Q4 2024. 343 funds tracked by Wall St. Rank hold RXRX as of Q2 2026.

FWL Investment Management held 55 shares of Recursion Pharmaceuticals worth $202 as of Q2 2026.
FWL Investment Management left its Recursion Pharmaceuticals share count unchanged in Q2 2026.
Recursion Pharmaceuticals made up ﹤0.01% of FWL Investment Management's portfolio in Q2 2026, its #498 holding.
FWL Investment Management first reported a position in Recursion Pharmaceuticals in Q4 2024 and has held it in 7 quarters since.
FWL Investment Management's Recursion Pharmaceuticals position peaked at $4.22K in Q4 2024.
343 funds tracked by Wall St. Rank held Recursion Pharmaceuticals as of Q2 2026.

Based on FWL Investment Management's 13F filing for Q2 2026, filed 14 Aug 2026.